Biomarin Pharmaceutical (BMRN) Asset Writedowns and Impairment (2012 - 2025)

Biomarin Pharmaceutical has disclosed Asset Writedowns and Impairment across 6 years of filings, most recently posting $116.2 million for Q4 2025.

• Quarterly Asset Writedowns and Impairment rose 684.45% year-over-year to $116.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $116.2 million (up 24623.42% YoY) and the FY2025 annual result came in at $119.2 million, changed N/A from the prior year.
• Asset Writedowns and Impairment climbed to $116.2 million in Q4 2025, from $3.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $116.2 million in Q4 2025 and troughed at -$19.9 million in Q4 2024.
• A 3-year average of $20.3 million and a median of $9.7 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment slumped 242.06% — and 2025, when it jumped 684.45%.
• Tracing BMRN's Asset Writedowns and Impairment over 3 years: stood at $14.0 million in 2023, then sank by 242.06% to -$19.9 million in 2024, then soared by 684.45% to $116.2 million in 2025.
• Business Quant data shows BMRN's Asset Writedowns and Impairment at $116.2 million in Q4 2025, $3.0 million in Q1 2025, and -$19.9 million in Q4 2024.